SNSS Sunesis Pharmaceuticals Inc

(1) Includes 40,600 Shares (as defined below) currently issuable upon the conversion of certain Series E Preferred (as defined below) and 110,771 Shares currently issuable upon the conversion of certain Series F Preferred (as defined below).

(1) Includes 40,600 Shares currently issuable upon the conversion of certain Series E Preferred and 110,771 Shares currently issuable upon the conversion of certain Series F Preferred.

(1) Includes 11,114 Shares currently issuable upon the conversion of certain Series E Preferred and 53,638 Shares currently issuable upon the conversion of certain Series F Preferred.

(1) Includes 11,114 Shares currently issuable upon the conversion of certain Series E Preferred and 53,638 Shares currently issuable upon the conversion of certain Series F Preferred.

(1) Includes 3,000 Shares currently issuable upon the conversion of Series E Preferred.

(1) Includes 3,000 Shares currently issuable upon the conversion of Series E Preferred.

(1) Includes 51,714 Shares currently issuable upon the conversion of certain Series E Preferred and 164,409 Shares currently issuable upon the conversion of Series F Preferred.

(1) Includes 54,714 Shares currently issuable upon the conversion of certain Series E Preferred and 164,409 Shares currently issuable upon the conversion of Series F Preferred.

(1) Includes 54,714 Shares currently issuable upon the conversion of certain Series E Preferred and 164,409 Shares currently issuable upon the conversion of Series F Preferred.

(1) Includes 54,714 Shares currently issuable upon the conversion of certain Series E Preferred and 164,409 Shares currently issuable upon the conversion of Series F Preferred.

Viracta Therapeutics, Inc., a Delaware corporation (the “Issuer”).

2533 S. Coast Hwy. 101, Suite 210

Cardiff, California 92007

Biotechnology Value Fund, L.P. (“BVF”)

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

BVF I GP LLC (“BVF GP”)

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Fund II, L.P. (“BVF2”)

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

BVF II GP LLC (“BVF2 GP”)

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Trading Fund OS LP (“Trading Fund OS”)

PO Box 309 Ugland House

Grand Cayman, KY1-1104

Cayman Islands

Citizenship: Cayman Islands

BVF Partners OS Ltd. (“Partners OS”)

PO Box 309 Ugland House

Grand Cayman, KY1-1104

Cayman Islands

Citizenship: Cayman Islands

BVF GP Holdings LLC (“BVF GPH”)

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

BVF Partners L.P. (“Partners”)

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

BVF Inc.

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

Mark N. Lampert (“Mr. Lampert”)

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: United States

Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

Common Stock, par value $0.0001 per share (the “Shares”)

92765F108

As of the close of business on December 31, 2022, the Reporting Persons held 1,915 Series E Preferred shares convertible for an aggregate of approximately 54,714 Shares (the “Series E Preferred”). The Series E Preferred may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), more than 9.98% of the number of Shares then issued and outstanding (the “Series E Blocker”). As of the close of business on December 31, 2022, the Series E Blocker did not limit the conversion of any of the Series E Preferred owned by the Reporting Persons. In providing beneficial ownership described herein, the Reporting Persons have assumed that all of the Series E Preferred held by the Reporting Persons would be converted.

As of the close of business on December 31, 2022, the Reporting Persons held 8,333 Series F Preferred shares convertible for an aggregate of approximately 238,086 Shares (the “Series F Preferred”). The Series F Preferred may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.98% of the number of Shares then issued and outstanding (the “Series F Blocker”). As of the close of business on December 31, 2022, the Series F Blocker limits the conversion of the Series F Preferred to 164,409 Shares out of the 238,086 Shares underlying the Series F Preferred in the aggregate. In providing beneficial ownership described herein, the Reporting Persons have assumed that all of the Series F Preferred held by BVF and certain of the Series F Preferred held by BVF2 would be converted.

As of the close of business on December 31, 2022 (i) BVF beneficially owned 1,992,047 Shares, including 40,600 Shares issuable upon the conversion of Series E Preferred held by it and 110,771 Shares issuable upon the conversion of Series F Preferred held by it; (ii) BVF2 beneficially owned 1,513,646 Shares, including 11,114 Shares issuable upon the conversion of Series E Preferred held by it and 53,638 Shares issuable upon the conversion of certain Series F Preferred held by it, and excluding 50,277 Shares underlying the remaining Series F Preferred held by it; and (iii) Trading Fund OS beneficially owned 260,654 Shares, including 3,000 Shares issuable upon the conversion of Series E Preferred held by it and excluding 15,857 Shares underlying the Series F Preferred held by it.

BVF GP, as the general partner of BVF, may be deemed to beneficially own the 1,992,047 Shares beneficially owned by BVF.

BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 1,513,646 Shares beneficially owned by BVF2.

Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 260,654 Shares beneficially owned by Trading Fund OS.

BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 3,505,693 Shares beneficially owned in the aggregate by BVF and BVF2.

Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 3,833,785 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in a certain Partners managed account (the “Partners Managed Account”), including 67,438 Shares, which excludes the 7,543 Shares underlying the Series F Preferred held in the Partners Managed Account.

BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 3,833,785 Shares beneficially owned by Partners.

Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 3,833,785 Shares beneficially owned by BVF Inc.

The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

The following percentages are based upon a denominator that is the sum of: (a) 38,197,345 Shares outstanding as of November 1, 2022 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2022, (b) certain or all of the 54,714 Shares that may be acquired upon the conversion of the Series E Preferred, as applicable and (c) certain or all of the 164,409 Shares that may be acquired upon the conversion of certain Series F Preferred, as applicable.

As of the close of business on December 31, 2022 (i) BVF beneficially owned approximately 5.2% of the outstanding Shares, (ii) BVF2 beneficially approximately 4.0% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 5.2% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 4.0% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 9.1% of the outstanding Shares, and (v) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 9.98% of the outstanding Shares (less than 1% of the outstanding Shares is held in the Partners Managed Account).

See Cover Pages Items 5-9.

See Cover Pages Items 5-9.

See Cover Pages Items 5-9.

See Cover Pages Items 5-9.

Not Applicable.

BVF GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF. BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by Trading Fund OS and held in the Partners Managed Account.

Not Applicable.

See Exhibit 99.1 to Amendment No. 6 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on February 14, 2020.

Not Applicable.

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2023